DK0792287T3 - Peptidanaloger af humant basisk myelinprotein - Google Patents

Peptidanaloger af humant basisk myelinprotein

Info

Publication number: DK0792287T3
Authority: DK; Denmark
Prior art keywords: peptide analogs; myelin protein; analogs; human basic; basic myelin
Prior art date: 1994-11-18

Application number

DK95942843T

Other languages

English (en)

Inventor

Lawrence Steinman

Nicholas Ling

Amitabh Gaur

Paul J Conlon

Original Assignee

Neurocrine Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-18

Filing date

1995-11-16

Publication date

2004-08-30

1995-11-16 Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc

2004-08-30 Application granted granted Critical

2004-08-30 Publication of DK0792287T3 publication Critical patent/DK0792287T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Rehabilitation Therapy (AREA)
Rheumatology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK95942843T 1994-11-18 1995-11-16 Peptidanaloger af humant basisk myelinprotein DK0792287T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/342,408 US6329499B1 (en)	1994-11-18	1994-11-18	Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein

Publications (1)

Publication Number	Publication Date
DK0792287T3 true DK0792287T3 (da)	2004-08-30

Family

ID=23341698

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95942843T DK0792287T3 (da)	1994-11-18	1995-11-16	Peptidanaloger af humant basisk myelinprotein

Country Status (13)

Country	Link
US (2)	US6329499B1 (da)
EP (2)	EP0792287B1 (da)
JP (1)	JPH10509172A (da)
AT (1)	ATE266043T1 (da)
AU (1)	AU4405896A (da)
CA (1)	CA2204147A1 (da)
DE (1)	DE69532996T2 (da)
DK (1)	DK0792287T3 (da)
ES (1)	ES2218559T3 (da)
MX (1)	MX9703643A (da)
NO (1)	NO972264L (da)
PT (1)	PT792287E (da)
WO (1)	WO1996016086A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6252040B1 (en)	1991-10-22	2001-06-26	The Governors Of The University Of Alberta	Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
CA2203629A1 (en) *	1994-10-25	1996-05-02	Dawn Smilek	Compositions and treatment for multiple sclerosis
US6379670B1 (en)	1994-11-18	2002-04-30	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
AU721898B2 (en)	1994-11-18	2000-07-20	Board Of Trustees Of The Leland Stanford Junior University	Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
US6329499B1 (en)	1994-11-18	2001-12-11	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6251396B1 (en) *	1994-11-18	2001-06-26	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US5874531A (en) *	1995-03-07	1999-02-23	President And Fellows Of Harvard College	Identification of self and non-self antigens implicated autoimmune disease
WO1996028470A2 (en) *	1995-03-09	1996-09-19	Neurocrine Biosciences, Inc.	Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
US6737057B1 (en)	1997-01-07	2004-05-18	The University Of Tennessee Research Corporation	Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
CA2201841C (en) *	1997-04-04	2010-01-26	The Governors Of The University Of Alberta	Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
AU7863701A (en)	2000-08-21	2002-03-04	Univ Bristol	Peptide selection method
MXPA03010037A (es) *	2001-05-01	2004-06-30	Univ California	Moleculas de fusion y metodos para tratamiento de enfermedades inmunes.
US7265208B2 (en)	2001-05-01	2007-09-04	The Regents Of The University Of California	Fusion molecules and treatment of IgE-mediated allergic diseases
CN100582085C (zh)	2002-10-10	2010-01-20	耶达研究及发展有限公司	脂肪醇的碱性酯及它们作为抗炎药或免疫调节剂的用途
US7084247B2 (en) *	2004-03-11	2006-08-01	Peptimmune, Inc.	Identification of self and non-self antigens implicated in autoimmune diseases
WO2006019982A2 (en) *	2004-07-15	2006-02-23	Vernalis Plc	Pin1-modulating compounds and methods of use thereof
US20060240032A1 (en) *	2005-03-31	2006-10-26	Hinrichs David J	Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
WO2007070660A2 (en)	2005-12-13	2007-06-21	President And Fellows Of Harvard College	Scaffolds for cell transplantation
WO2009002401A2 (en)	2007-06-21	2008-12-31	President And Fellows Of Harvard College	Scaffolds for cell collection or elimination
US9370558B2 (en)	2008-02-13	2016-06-21	President And Fellows Of Harvard College	Controlled delivery of TLR agonists in structural polymeric devices
WO2009102465A2 (en)	2008-02-13	2009-08-20	President And Fellows Of Harvard College	Continuous cell programming devices
US9012399B2 (en)	2008-05-30	2015-04-21	President And Fellows Of Harvard College	Controlled release of growth factors and signaling molecules for promoting angiogenesis
WO2010120749A2 (en)	2009-04-13	2010-10-21	President And Fellow Of Harvard College	Harnessing cell dynamics to engineer materials
EP2461828B1 (en)	2009-07-31	2017-06-21	President and Fellows of Harvard College	Programming of cells for tolerogenic therapies
WO2011109834A2 (en)	2010-03-05	2011-09-09	President And Fellows Of Harvard College	Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1
WO2011163669A2 (en)	2010-06-25	2011-12-29	President And Fellows Of Harvard College	Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
SI2624873T1 (sl)	2010-10-06	2020-07-31	President And Fellows Of Harvard College	Injektabilni, pore-formirajoči hidrogeli za celične terapije - na osnovi materialov
WO2012064697A2 (en)	2010-11-08	2012-05-18	President And Fellows Of Harvard College	Materials presenting notch signaling molecules to control cell behavior
WO2012148684A1 (en)	2011-04-27	2012-11-01	President And Fellows Of Harvard College	Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
ES2685327T3 (es)	2011-04-28	2018-10-08	President And Fellows Of Harvard College	Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
US9675561B2 (en)	2011-04-28	2017-06-13	President And Fellows Of Harvard College	Injectable cryogel vaccine devices and methods of use thereof
WO2012167230A1 (en)	2011-06-03	2012-12-06	President And Fellows Of Harvard College	In situ antigen-generating cancer vaccine
ES2773895T3 (es)	2012-04-16	2020-07-15	Harvard College	Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
EP3137105A4 (en)	2014-04-30	2017-12-27	President and Fellows of Harvard College	Combination vaccine devices and methods of killing cancer cells
HK1247861A1 (zh)	2015-01-30	2018-10-05	President And Fellows Of Harvard College	用於癌症治疗的肿瘤周围和肿瘤内部材料
CN114099793A (zh)	2015-04-10	2022-03-01	哈佛学院院长等	免疫细胞捕获装置及其制备和使用方法
WO2017136837A1 (en)	2016-02-06	2017-08-10	President And Fellows Of Harvard College	Recapitulating the hematopoietic niche to reconstitute immunity
EP4606890A3 (en)	2016-07-13	2025-12-03	President and Fellows of Harvard College	Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
KR102638898B1 (ko)	2016-08-02	2024-02-22	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	면역 반응을 조정하기 위한 생체재료
WO2020061129A1 (en)	2018-09-19	2020-03-26	President And Fellows Of Harvard College	Compositions and methods for labeling and modulation of cells in vitro and in vivo
EP4034148A4 (en)	2019-09-23	2025-09-10	Harvard College	BIOMATERIAL-BASED ANTIGEN-FREE VACCINE AND ITS USE

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1340012C (en)	1987-08-17	1998-08-25	Trustees Of Leland Stanford Jr. University	Peptide determinant associated with immunity
US5468481A (en) *	1988-06-23	1995-11-21	Amergen, Inc.	MHC class II-peptide conjugates useful in ameliorating autoimmunity
GB8915019D0 (en) *	1989-06-30	1989-08-23	Matthews Ruth C	Medicaments
JPH05508621A (ja)	1990-03-02	1993-12-02	オートイミューン　インク	自己抗原の経口投与による自己免疫疾患のダウンコントロール
US6036957A (en)	1990-03-30	2000-03-14	Autoimmune, Inc.	Suppression of T-cell proliferation using peptide fragments of myelin basic protein
DE69230612T2 (de)	1991-05-31	2000-06-21	Connetics Corp., Palo Alto	T-zell rezeptorpeptide als therapeutika für immun-verwandte krankheiten
US5817629A (en)	1991-10-22	1998-10-06	The Governors Of The University Of Alberta	Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
CA2053799C (en)	1991-10-22	2002-03-12	Kenneth G. Warren	Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
EP0650498B1 (en)	1992-04-09	1998-09-09	Autoimmune, Inc.	Suppression of t-cell proliferation using peptide fragments of myelin basic protein
JPH06157591A (ja) *	1992-11-27	1994-06-03	Teijin Ltd	抗凝固性ペプチド
US5559209A (en) *	1993-02-18	1996-09-24	The General Hospital Corporation	Regulator regions of G proteins
AU695801B2 (en)	1993-09-22	1998-08-20	Board Of Trustees Of The Leland Stanford Junior University	Interaction of T-cell receptors and antigen in autoimmune disease
US6329499B1 (en)	1994-11-18	2001-12-11	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
AU721898B2 (en)	1994-11-18	2000-07-20	Board Of Trustees Of The Leland Stanford Junior University	Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
WO1996028470A2 (en)	1995-03-09	1996-09-19	Neurocrine Biosciences, Inc.	Peptide analogues of human myelin basic protein useful in treating multiple sclerosis

1994
- 1994-11-18 US US08/342,408 patent/US6329499B1/en not_active Expired - Fee Related
1995
- 1995-11-16 AU AU44058/96A patent/AU4405896A/en not_active Abandoned
- 1995-11-16 ES ES95942843T patent/ES2218559T3/es not_active Expired - Lifetime
- 1995-11-16 WO PCT/US1995/014403 patent/WO1996016086A1/en not_active Ceased
- 1995-11-16 PT PT95942843T patent/PT792287E/pt unknown
- 1995-11-16 CA CA002204147A patent/CA2204147A1/en not_active Abandoned
- 1995-11-16 EP EP95942843A patent/EP0792287B1/en not_active Expired - Lifetime
- 1995-11-16 AT AT95942843T patent/ATE266043T1/de not_active IP Right Cessation
- 1995-11-16 DE DE69532996T patent/DE69532996T2/de not_active Expired - Fee Related
- 1995-11-16 DK DK95942843T patent/DK0792287T3/da active
- 1995-11-16 JP JP8516911A patent/JPH10509172A/ja active Pending
- 1995-11-16 EP EP03028981A patent/EP1440980A3/en not_active Withdrawn
- 1995-11-16 MX MX9703643A patent/MX9703643A/es unknown
1997
- 1997-05-16 NO NO972264A patent/NO972264L/no unknown
2001
- 2001-12-11 US US10/015,540 patent/US20020086976A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0792287A1 (en)	1997-09-03
ES2218559T3 (es)	2004-11-16
JPH10509172A (ja)	1998-09-08
EP0792287B1 (en)	2004-05-06
DE69532996T2 (de)	2005-04-14
EP1440980A3 (en)	2005-01-19
WO1996016086A1 (en)	1996-05-30
NO972264D0 (no)	1997-05-16
MX9703643A (es)	1997-08-30
ATE266043T1 (de)	2004-05-15
DE69532996D1 (de)	2004-06-09
US20020086976A1 (en)	2002-07-04
EP1440980A2 (en)	2004-07-28
CA2204147A1 (en)	1996-05-30
PT792287E (pt)	2004-09-30
AU4405896A (en)	1996-06-17
NO972264L (no)	1997-07-16
US6329499B1 (en)	2001-12-11

Publication	Publication Date	Title
DK0792287T3 (da)	2004-08-30	Peptidanaloger af humant basisk myelinprotein
AU6020099A (en)	2000-03-14	Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
ATE108662T1 (de)	1994-08-15	Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
RU95115239A (ru)	1997-03-27	Аналог эритропоэтина
PT662827E (pt)	2002-09-30	Metodos de diagnostico e composicoes farmaceuticas a base de proteinas notch e acidos nucleicos
PT725824E (pt)	2003-08-29	Epitopos de celulas t humanas imunodominantes do virus da hepatite c
WO1996028470A3 (en)	1996-11-14	Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
DE69525544D1 (de)	2002-03-28	Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
BR9507758A (pt)	1997-09-23	Fração de copolímero-1 e composição para o tratamento de esclerose múltipla
TR200003048T2 (tr)	2000-12-21	İnsülinin peptit analoglarının diyabet tedavisi için kullanımı.
ES2168354T3 (es)	2002-06-16	Protegrinas.
ATE121755T1 (de)	1995-05-15	Deletionsanaloga von magaininpeptiden.
BR9306272A (pt)	1998-06-23	Peptídeo e composiçao farmacêutica
GB9606040D0 (en)	1996-05-22	Active peptide
MX9203175A (es)	1993-04-01	Composicion de implante que contiene un peptido, polipeptido o proteina biologicamente activa y procedimiento para su preparacion.
IL95863A0 (en)	1991-07-18	Anticoagulant peptides and compositions containing them
ES2080060T3 (es)	1996-02-01	Proteinas que tienen actividad de union a interferon-gamma.
DE69636052D1 (de)	2006-05-24	Mpl-liganden analoga
ATE42308T1 (de)	1989-05-15	Pharmakologisch aktive peptide.
HU896448D0 (en)	1990-02-28	Process for the preparation of anticoagulant peptides
DE69032574D1 (de)	1998-09-24	Antibakterielle- und antimalariapeptide
EP0490383A3 (en)	1993-06-30	Peptides of the hiv-gag protein, their preparation and use
ES2023746A6 (es)	1992-02-01	Procedimiento de preparacion de peptidos de serina-acido aspartico- lisina
ATE27822T1 (de)	1987-07-15	Hexapeptid, verfahren zur herstellung und pharmazeutische zusammensetzungen hieraus.